Biology basic
Cracking RAS: It took over 30 years to hit this ubiquitous oncogene – was it worth the wait?
RAS oncogenes and their proteins have central roles in almost all cancers, including leukaemias, multiple myelomas, skin cancers and many solid tumours, making the RAS protein family an ideal cancer…
The CRISPR revolution: it’s transforming cancer research, can it do the same for treatment?
CRISPR is a revolutionary gene-editing tool that allows scientists to cut DNA with extraordinary precision and make changes to the genome. The technology was a gift to cancer researchers, whose…
A blood test for early detection of any cancer: What’s the ideal? Are we getting there?
Earlier cancer diagnosis could make a huge difference to cancer survival rates – only two in ten of those diagnosed after their cancer has metastasised survive, compared with nine in…
Nanotechnology is steadily expanding its many roles in tackling cancer
A nanomedicine, as defined by the US National Institutes of Health, is a “highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues… ” For…
Cancer and the immune system: turning insights into treatments
The vision of harnessing our immune systems to fight cancer has been tantalising scientists and doctors for more than a century. The idea had a strong scientific rationale: over millions…
How organoids could help match treatments to tumours
When diagnosed with cancer, few things are more important than having confidence that the treatment you are prescribed is the best possible option for you. For many cancers, particularly the…
What can we expect from mRNA cancer vaccines?
Messenger RNA vaccines turned around Europe’s fight against the Covid pandemic. Less than a year after the first lockdowns were declared, mRNA vaccines got regulatory approval for emergency use, first…
Tackling drug resistance: how our commensal bacteria can hinder or help
Response to therapeutics can differ widely from patient to patient, with some gaining highly significant survival benefits from a therapy that in others elicits no response at all. Patients who…
The development of organoids for cancer research: an ode to the scientific method
Some twenty years ago, I sailed with my two little sons Sander (aged 7) and Max (aged 5) on the Ijsselmeer, formerly a large inner sea in the centre of…
Natural killers: a new tactical unit joins the cancer immunotherapy brigade
There was a time when all that oncologists treating solid tumours needed to know about leukocytes was how to measure the damage that cytotoxic drugs inflicted on their patients’ white…